Arcus Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Arcus Biosciences's estimated annual revenue is currently $37.9M per year.
- Arcus Biosciences received $107.0M in venture funding in November 2017.
- Arcus Biosciences's estimated revenue per employee is $75,288
- Arcus Biosciences's total funding is $647.1M.
- Arcus Biosciences's current valuation is $2.5B. (January 2022)
- Arcus Biosciences has 503 Employees.
- Arcus Biosciences grew their employee count by 39% last year.
Arcus Biosciences Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Arcus Biosciences?
Arcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world's largest biotechnology research hub. Unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. For this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. Arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. These new drugs will then be deployed in various combinations to combat cancer. We are growing very actively and are always interested in hearing from scientists with a recent PhD in Chemistry, Immunology and one of the quantitative life sciences (Biochemistry, Enzymology, Molecular Pharmacology, etc). We also have openings for experienced researchers with ten or more years assay development experience applied either in the context of SAR support or clinical PD marker assays. If this describes you, please check out the opportunities on our website at www.arcusbio.comkeywords:N/A
Number of Employees
Employee Growth %
Arcus Biosciences News
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for...
By Chris Wack. Arcus Biosciences Inc. shares rose 12% to $39.15 after S&P Dow Jones Indices added it to the S&P SmallCap 600.
Arcus Biosciences (NYSE:RCUS) has jumped 9.7% postmarket on the news it's set to join the S&P SmallCap 600 index. It's moving in to replace...
HAYWARD, Calif.--(BUSINESS WIRE)--Mar 9, 2021-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees opt ...
HAYWARD, Calif.--(BUSINESS WIRE)--Feb 24, 2021-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided operational ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Arcus Biosciences Funding
|2016-08-31||$70.0M||B||Arcus Biosciences Inc||Article|